Cargando…
Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps
Aim: The efficacy and safety of allergen immunotherapy (AIT) in allergic rhinitis has been classically assessed using randomized controlled trials (RCTs). However, RCTs may have limitations in their external validity, and their evidence may be complemented with that from real-world studies. We aimed...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012883/ https://www.ncbi.nlm.nih.gov/pubmed/36925994 http://dx.doi.org/10.5414/ALX02343E |
_version_ | 1784906701039730688 |
---|---|
author | Sousa-Pinto, Bernardo Pfaar, Oliver Bousquet, Jean |
author_facet | Sousa-Pinto, Bernardo Pfaar, Oliver Bousquet, Jean |
author_sort | Sousa-Pinto, Bernardo |
collection | PubMed |
description | Aim: The efficacy and safety of allergen immunotherapy (AIT) in allergic rhinitis has been classically assessed using randomized controlled trials (RCTs). However, RCTs may have limitations in their external validity, and their evidence may be complemented with that from real-world studies. We aimed to review the mHealth apps that can be used for retrieving real-world data on AIT in allergic rhinitis. Materials and methods: We applied an automatic tool to identify the mHealth apps (available in the Google Play and Apple App stores) that can be used to assess patients under AIT for allergic rhinitis. Apps meeting the inclusion criteria were reviewed, and the corresponding scientific evidence was assessed. Results: We identified five apps with scientific publications in the context of allergic rhinitis: AirRater, AllergyMonitor, MASK-air, Husteblume, and Pollen App. Of those, only MASK-air and AllergyMonitor assessed AIT in patients with allergic rhinitis. MASK-air has enabled the comparison of reported symptoms among patients treated vs. not-treated with AIT. MASK-air has also allowed for the development of combined symptom-medication scores that can be used as endpoints for AIT trials. AllergyMonitor has identified that mobile technology can improve adherence to AIT and is set to support the prescription of AIT for patients with allergic rhinitis by a more precise identification of the pollen season. Conclusion: Mobile health tools allow for the collection of large volumes of real-world data and can be useful for generating hypotheses on AIT. However, such hypotheses require confirmation by epidemiological studies and RCTs. |
format | Online Article Text |
id | pubmed-10012883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-100128832023-03-15 Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps Sousa-Pinto, Bernardo Pfaar, Oliver Bousquet, Jean Allergol Select Review Article Aim: The efficacy and safety of allergen immunotherapy (AIT) in allergic rhinitis has been classically assessed using randomized controlled trials (RCTs). However, RCTs may have limitations in their external validity, and their evidence may be complemented with that from real-world studies. We aimed to review the mHealth apps that can be used for retrieving real-world data on AIT in allergic rhinitis. Materials and methods: We applied an automatic tool to identify the mHealth apps (available in the Google Play and Apple App stores) that can be used to assess patients under AIT for allergic rhinitis. Apps meeting the inclusion criteria were reviewed, and the corresponding scientific evidence was assessed. Results: We identified five apps with scientific publications in the context of allergic rhinitis: AirRater, AllergyMonitor, MASK-air, Husteblume, and Pollen App. Of those, only MASK-air and AllergyMonitor assessed AIT in patients with allergic rhinitis. MASK-air has enabled the comparison of reported symptoms among patients treated vs. not-treated with AIT. MASK-air has also allowed for the development of combined symptom-medication scores that can be used as endpoints for AIT trials. AllergyMonitor has identified that mobile technology can improve adherence to AIT and is set to support the prescription of AIT for patients with allergic rhinitis by a more precise identification of the pollen season. Conclusion: Mobile health tools allow for the collection of large volumes of real-world data and can be useful for generating hypotheses on AIT. However, such hypotheses require confirmation by epidemiological studies and RCTs. Dustri-Verlag Dr. Karl Feistle 2023-03-01 /pmc/articles/PMC10012883/ /pubmed/36925994 http://dx.doi.org/10.5414/ALX02343E Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Sousa-Pinto, Bernardo Pfaar, Oliver Bousquet, Jean Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title | Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title_full | Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title_fullStr | Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title_full_unstemmed | Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title_short | Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps |
title_sort | real-life evidence in allergen immunotherapy: moving forward with mhealth apps |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012883/ https://www.ncbi.nlm.nih.gov/pubmed/36925994 http://dx.doi.org/10.5414/ALX02343E |
work_keys_str_mv | AT sousapintobernardo reallifeevidenceinallergenimmunotherapymovingforwardwithmhealthapps AT pfaaroliver reallifeevidenceinallergenimmunotherapymovingforwardwithmhealthapps AT bousquetjean reallifeevidenceinallergenimmunotherapymovingforwardwithmhealthapps |